Research Article

Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China

Yanyun Chen,1 Wenbin Wei,1 Demetrios G. Vavvas,2 Feng Zhang,1 Haicheng She,1 Haiying Zhou,1 Lei Li,1 Yao Huang,1 Dimitrios P. Ntentakis,2 and Xiangyu Shi*1

1Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University, Beijing, China
2Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA

Correspondence should be addressed to Xiangyu Shi; sxy_bj@126.com

Received 10 May 2020; Revised 1 October 2020; Accepted 24 October 2020; Published 16 November 2020

1.Introduction

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are considered the standard treatment for patients with neovascular age-related macular degeneration (AMD), diabetic retinopathy (DR), and macular edema secondary to retinal vein occlusion. However, the significant therapeutic benefits over the years have not been completely free of complications. Following any intravitreal injection, there is always a risk of non-infectious or infectious endophthalmitis (EO). Non-infectious EO refers to a transient, self-limited inflammatory reaction, typically with hypopyon, presenting within the first few days after injections [1]. Infectious EO is overall the most feared complication of intravitreal injections. Typical bacterial EO presents with rapid visual loss, eye pain, conjunctival hyperemia, hypopyon, and vitreous opacification [2]. Bacterial infections account for the majority of such cases [3].

Variations in post-injection EO incidence might be explained by the different injection protocols, procedure settings (operating room (OR) versus office-based), and prophylactic antibiotics. In a retrospective multicenter study in Europe, EO incidence was reported lower (1/13,470) because anti-VEGF injections were administered in the higher sterility environment of an OR [4]. Meanwhile, intravitreal injections performed in the office setting achieved a comparatively low EO rate (0.009%) in a retrospective review of 10,142 consecutive cases [5]. Topical antibiotic prophylaxis is still controversial [6, 7], but more and more studies report low EO incidence without prophylaxis [8, 9]. In one study, the EO rate in the group with topical antibiotic prophylaxis after intravitreal injection was...
similar to that in the group without prophylaxis [8]. Using conjunctival sac irrigation with 0.25% povidone-iodine (PVI) before and after intravitreal injection, the EO incidence (0/12,523, 95% CI 0–0.00024%) remained low without pre- or post-injection topical antibiotics in a Japanese study [9].

Over the last decade, anti-VEGF injection demand has exponentially increased in China. In compliance with the 2015 Chinese Ocular Fundus Society (COFS) guidelines, intravitreal injections are performed in an OR, using 5% PVI irrigation before the injection, and topical antibiotics pre- and post-injection [10]. Compared to other countries [5, 9], the injection setting and the use of prophylactic antibiotics might be slightly different in China. Nonetheless, no report of post-injection EO has been documented to date.

This study presents post-injection EO rates from the largest eye center in mainland China, while co-evaluating the most frequent pathogens, visual outcomes, and potential risk factors.

2. Subjects and Methods

2.1. Subjects. All patients who had received intravitreal anti-VEGF injections with ranibizumab (Lucentis; Novartis AG, Basel, Switzerland) and conbercept (Lumitin; Kanghong Biotech, Chengdu, PR China) between September 2012 and December 2017 were enrolled. The injections were performed at the Beijing Tongren Eye Center, Beijing, China. Presumed EO was defined as any intraocular inflammation treated with tap and inject, with or without vitrectomy. Aqueous humor and vitreous samples were cultured. All presumed EO cases were included regardless of the subsequent culture results, positive or negative. EO cases were excluded from our study if the intravitreal injection had been combined with another ocular procedure (i.e., cataract operation, vitrectomy, laser, and panretinal photocoagulation). Informed consent was obtained from all patients before the injections. Our study was conducted in accordance with the tenets of the Declaration of Helsinki and approved by the Ethics Committee of the Beijing Tongren Hospital, Capital Medical University. The minimum follow-up duration for all cases in this study was one year.

2.2. Intravitreal Injection. Our procedures complied with the 2015 consensus of the COFS [10]. All intravitreal injections were performed in the OR without laminar airflow. All physicians wore disposable caps and surgical masks. Hand and arm disinfection was followed by the use of sterile disposable surgical gowns. Disposable clothing and surgical caps were worn by the patients as well. Additional sterilization measures included local antiseptics, sterile drapes, and sterile gloves. Disposable injection sets and all necessary instruments were prepared on a sterile tray. Periocular scrub with 10% PVI was performed three times per case before the injection. An adhesive surgical drape and a sterile eyelid speculum were used. All injections were preceded by 5% PVI rinsing of the fornices for at least 90 seconds, which was then washed out twice using 0.9% normal saline. A 30-gauge (G) needle was used for the procedure while avoiding any contact with the eyelids and the speculum. Topographically, the entry site was set at 3.5 mm posterior to the limbus in pseudophakic/aphakic eyes and at 4.0 mm from the limbus in phakic eyes. After the injection, antibiotic ointment (tobramycin and dexamethasone ophthalmic ointment) was applied on the lid conjunctiva, and the periorbital region was gently cleaned using sterile compresses. All patients received levofloxacin eye drops four times per day for 3 days pre-injection and 3 days post-injection.

2.3. Statistical Analysis. Confidence intervals were calculated by using the Wilson score method without continuity correction. The confidence limits for the relative risk reduction are one minus the confidence limits for the relative risk. Fisher’s exact probability method was used to compare the EO incidence between ranibizumab and conbercept groups.

3. Results

A total of 37,830 intravitreal anti-VEGF injections were performed at Beijing Tongren Eye Center from September 2012 to December 2017. Three cases of presumed EO were documented in 33,930 (ranibizumab, 95% CI: −0.0012% to 0.0188%) and 0 in 3,900 (conbercept). A combined incidence per injection is 0.0079% (1/12,610). There was no significant difference between the two drugs (P = 0.745).

EO cases were presented in June 2014 (Case 1), June 2015 (Case 2), and May 2017 (Case 3), respectively. All 3 presumed EO cases were initially managed with tap and inject at the emergency OR. After 24 hours, each case was evaluated based on visual acuity (VA) measurements, as well as the presence of eye pain, redness, and vitreous opacification. In all 3 cases, the aforementioned clinical signs persisted and rapidly worsened, accompanied by declining visual acuity during follow-up. Thus, pars plana vitrectomy (PPV) was immediately performed on follow-up day 1. Positive cultures were drawn from 2 of 3 cases, revealing Staphylococcus epidermidis and Streptococcus pneumoniae, respectively. Each patient’s ophthalmologic history, demographics, intraocular pathogen, and associated comorbidities such as high myopia, diabetes mellitus, and AMD are summarized in Table 1.

4. Discussion

Intravitreal injection of anti-VEGF has revolutionized the management and visual prognosis for patients with AMD, diabetic macular edema, and other diseases, resulting in retinal vascular leakage or choroidal neovascularization. Each such procedure is independently associated with a small risk of EO, ranging from 1 in 2,000 to 1 in 10,000 [4, 11–13]. EO post-injection may represent about 8.5% of the total EO cases [14].

The number of patients receiving intravitreal injections is continuously increasing. As procedural changes have been continuously evolving to reduce injection-related injury and infection, low EO rates can be achieved [15–17]. Our study
positive cultures (one case of incidence per injection (0.0079% or 1/12,610) with 2 out of 3 different sites [4]. In our study, we found a similar combined were given, and postoperative antibiotics varied among the three European sites where 134,701 intravitreal injections were performed via a standardized sterile technique in the first 5 years of the study and then, only to patients with diabetes [29]. Post-injection incidence for intravitreal injections performed in an outpatient setting versus an OR. As intravitreal injections have significantly increased over the past few years, an office-based setting might not only be more efficient but also more affordable and comparably safe.

Since there is always a risk of infectious or non-infectious endophthalmitis following any intravitreal injection, we should be vigilant to eliminate confounders. In general, eyes with marked fibrin, severe eye pain, and profound vision loss are more likely to be infectious EO. In contrast, eyes with minimal or absent fibrin, no pain or mild pain, self-limited, and better vision are probably non-infectious EO [1]. Non-infectious postinjection EO rates vary amongst studies [21]. Cases tended to cluster instead of occurring at a consistent rate every year. Yamashiro et al. reported that 14 eyes developed sterile endophthalmitis post-injection from a single batch [22]. Similarly, Entezari et al. reported 11 eyes developed sterile endophthalmitis after intravitreal bevacizumab injections from the same batch [23]. Pain, redness, and decreased vision began 11–17 days post-injection, yet prognosis was favorable for all cases eventually. On the other hand, non-infectious EO incidence may vary with different drugs. For instance, non-infectious EO incidence was higher for bevacizumab compared with ranibizumab and aflibercept [24]. In our study, all 3 EO cases progressed very rapidly with severe eye pain, worsening conjunctival hyperemia, and vitreous body opacification. Even though 1 case was culture-negative, it was also regarded as infectious EO due to its clinical manifestations.

In our study, the underlying diseases of the 3 presumed EO cases were pathologic myopia, diabetic retinopathy, AMD with entropion, and blepharitis. Scleral thinning secondary to high myopia, increased predisposition to infection with diabetes and as well as the propensity of conjunctivitis due to entropion and blepharitis are well-known EO risk factors. The patient with pathologic myopia also reported washing her hair within less than 24 h after the injection. Multiple injections and myopia-related scleral thinning might also increase the risk of bacteria invasion through the thinner scleral tunnel into the vitreous body. Since diabetics have an increased prevalence of infections [25], some studies have suggested that endophthalmitis following invasive ophthalmic procedures such as cataract surgery or PPV may occur more frequently in patients with diabetes [26, 27]. Post-injection EO rates have been reported higher in eyes with diabetes (0.049%) compared with eyes with retinal vein occlusion (0.012%, \( P = 0.010) \) [28]. In a retrospective study, 8 EO cases occurred among 15,925 intravitreal injection. Of these, 3 cases (3/8) had a history of diabetes [29]. Although culture-negative, one of the three presumed EO cases in our study was also diabetic. Given the well-known susceptibility of diabetics to prolonged asymptomatic infections, we suggest that more attention should be paid to all such patients requiring intravitreal injections.

There was no difference in EO rates between different anti-VEGF drugs (\( P = 0.745) \) in our study. Our results agree with previous reports in this field. In one of them, the EO incidence using ranibizumab, aflibercept, and bevacizumab was 0.020%, 0.021%, and 0.020%, respectively, with no significant difference between the drugs (\( P = 0.896) \) [24]. In a multicenter retrospective cohort study, 183 presumed EO cases were identified from a total of 503,890 anti-VEGF injections [30]. EO rate following intravitreal bevacizumab

| Case 1 | 23 | F | 7 | 2 | 0.6 | HM | 0.3 | Staphylococcus epidermidis | Myopic CNV, washing hair on the day of injection |
| Case 2 | 60 | M | 1 | 2 | HM | HM | FC | Negative | Diabetic retinopathy, diabetes mellitus |
| Case 3 | 67 | M | 1 | 4 | LP | LP | FC | Streptococcus pneumonia | AMD, entropion, and blepharitis |

M: male; F: female; BCVA: best-corrected visual acuity; Dx: diagnosis; HM: hand movement; CNV: choroidal neovascularization; FC: finger counting; LP: light perception.
(0.039%, 60/153,812), ranibizumab (0.035%, 109/309,722),
and aflibercept (0.035%, 14/40,356) injection again appeared similar [30]. Therefore, we suggest that the choice of anti-VEGF agents should be primarily based on their individualized clinical efficacy rather than the potential risk of infection.

Despite its low mathematical value, EO risk independently increases for any patient receiving a new intravitreal injection. 5% PVI effectively disrupts conjunctival bacterial colonies, and 30 seconds of exposure appears to be an adequate time to decrease conjunctival bacterial counts [31]. PVI has the advantage of not invoking drug resistance, unlike antibiotics [32]. The use of pre- and post-injection topical antibiotics for prophylaxis has been debated [12, 33–36]. Widespread use of prophylactic antibiotics may underline the alarming rates of antibacterial treatment failure and antibiotic resistance. In a retrospective case-control study of 172,096 anti-VEGF injections [33], 28 EO cases (10 culture-positive) occurred among 57,654 injections with post-injection antibiotic prophylaxis versus 24 EO cases (6 culture-positive) among 89,825 injections without antibiotics. In the post-injection antibiotics use cohort, four out of ten (40%) culture-positive cases grew bacteria resistant to the prescribed prophylactic antibiotics. In contrast, none of the six culture-positive cases in the cohort without post-injection antibiotics use grew resistant bacteria (odds ratio = 9.0; 95% confidence interval = 0.40–203.3; P = 0.17). This study suggested that prophylactic topical antibiotics following intravitreal injection may lead to higher rates of antibiotic-resistant bacteria in culture-positive EO cases [33]. A recent systematic review further advocates that antibiotic prophylaxis does not reduce the post-injection EO rate, while it might potentially be associated with an increased risk of post-operative infection [7]. Similarly, EO incidence might not increase without antibiotics. In one study, all non-diabetic patients (approximately 7,000 injections) were treated without post-injection topical antibiotics and no one suffered from EO [18]. Thus, omitting topical antibiotics might be safe in patients without diabetes. In our study, all patients received levofloxacin eye drops four times per day for 3 days pre-injection and 3 days post-injection. However, our EO incidence was not lower than other reports. Our results further advocate that overall EO rates do not decrease even with prophylactic antibiotics. In 2015, American Society of Retina Specialists (ASRS) Annual Preferences and Trends (PAT) survey reported an ongoing divergence between US and international members about topical antibiotics use in intravitreal injections: 9.5% of US members reported using topical antibiotics, as opposed to 60.6% of international members [37]. In 2016, the PAT survey showed only 8.8% of US members and 53.5% of international members reported use of topical antibiotics [38]. The PAT survey reveals a decline in topical antibiotics over the years. Based on many newer published series of intravitreal injections without topical antibiotics [8, 9], it is possible that non-US ophthalmologists will increasingly forgo topical antibiotics with intravitreal injections.

Regardless of the injection setting and antibiotic prophylaxis, prefilled syringes as well as the large-gauge needles used in long-term release devices might also affect EO incidence [39–41]. In our study, ranibizumab and conbercept were packaged in a glass vial and aspirated with a large bore needle before injection. None of prefilled syringes were used in this study.

The current study has several limitations. First, it is a single-center retrospective study. Second, the OR without laminar airflow might affect EO incidence. Third, with the combination of prophylactic topical antibiotics and irrigation with 5% PVI rinsing before the procedure, we cannot distinguish the role of antibiotics versus 5% PVI alone. Finally, the intravitreal injection in this study is OR-based. An OR setting not only increases the cost but also prolongs waiting hours for the patients. Combined with the rapidly increasing demand for intravitreal injections in China, an outpatient setting should be explored in an attempt to enhance efficiency and cost-effectiveness. To date, though we have no data for intravitreal injections performed in a clinical office. From our standpoint, a prospective study monitoring post-injection EO rates in a standardized outpatient setting in China would be extremely beneficial for the optimization of healthcare practices in the country.

5. Conclusions

In conclusion, a standardized sterile technique in an OR showed very low EO rates at mainland China. However, EO could not be completely avoided.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors would like to thank all the surgeons who operated intravitreal injections and those that have helped them to collect patients’ data.

References

[1] D. B. Roth and H. W. Flynn Jr., “Distinguishing between infectious and non-infectious endophthalmitis after intravitreal triamcinolone injection,” American Journal of Ophthalmology, vol. 146, no. 3, pp. 346–347, 2008.
[2] A. A. Moshfeghi, P. J. Rosenfeld, H. W. Flynn Jr. et al., “Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists,” Retina, vol. 31, no. 4, pp. 662–668, 2011.
[3] M. Kernt and A. Kampik, “Endophthalmitis: pathogenesis, clinical presentation, management, and perspectives,” Clinical Ophthalmology, vol. 4, pp. 121–135, 2010.
[4] F. J. Freiberg, T. Brynskov, M. R. Munk et al., “Low endophthalmitis rates after intravitreal anti-vascular endothelial growth factor injections in an operation room,” Retina, vol. 37, no. 12, pp. 2341–2346, 2017.
[5] L. L. Cavalcante, M. L. Cavalcante, T. G. Murray et al., “Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis,” Clinical Ophthalmology, vol. 4, pp. 519–524, 2010.

[6] C. Benoist d’Azy, B. Pereira, G. Naughton, F. Chiam baretta, and F. Dutheil, “Antibiotic prophylaxis in prevention of endophthalmitis in intravitreal injection: a systematic review and meta-analysis,” PLoS One, vol. 11, no. 6, Article ID e0156431, 2016.

[7] F. Menchini, G. Toneatto, A. Miele, S. Donati, P. Lanzetta, and C. Benoist d’Azy, B. Pereira, G. Naughton, F. Chiambaretta, and G. Virgili, “Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review,” Eye, vol. 32, no. 9, pp. 1423–1431, 2018.

[8] S. Torres-Costa, D. Ramos, E. Brandão et al., “Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis,” European Journal of Ophthalmology, Article ID 112067212092028, 2020.

[9] K. Tanaka, H. Shimada, R. Mori, H. Nakashizuka, T. Hattori, and Y. Okubo, “No increase in risk of post-intravitreal injection endophthalmitis without topical antibiotics: a prospective study,” Japanese Journal of Ophthalmology, vol. 63, no. 5, pp. 496–501, 2019.

[10] Chinese Medical Association, “Quality control standards of intravitreal injection of medications to treat retinopathy in China,” Chinese Journal of Ophthalmology, vol. 51, no. 12, pp. 892–895, 2015.

[11] C. A. McCannel, “Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents,” Retina, vol. 31, no. 4, pp. 654–661, 2011.

[12] C. S. Y. Cheung, A. W. T. Wong, A. Lui, P. J. Kertes, R. G. Devenyi, and W.-C. Lam, “Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections,” Ophthalmology, vol. 119, no. 8, pp. 1609–1614, 2012.

[13] D. Dossarps, A. M. Bron, P. Krohmer, L. S. Aho-Glélé, and C. Creuzot-Garcher, “Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome,” American Journal of Ophthalmology, vol. 160, no. 1, pp. 17–25, 2015.

[14] M. M. Sachdeva, A. Moshiri, H. A. Leder, and A. W. Scott, “Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms,” Journal of Ophthalmic Inflammation and Infection, vol. 6, no. 1, p. 2, 2016.

[15] P. E. Lau, K. S. Jenkins, and C. J. Layton, “Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections,” Journal of Ophthalmology, vol. 2018, p. 8, Article ID 8567912, 2018.

[16] R. L. Avery, S. J. Bakri, M. S. Blumenkranz et al., “Intravitreal injection technique and monitoring,” Retina, vol. 34, no. Suppl 1, pp. S1–S18, 2014.

[17] R. Merani and A. P. Hunyor, “Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review,” International Journal of Retina and Vitreous, vol. 1, no. 1, p. 9, 2015.

[18] T. Brynskov, H. Kemp, and T. L. Sørensen, “No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting,” Retina, vol. 34, no. 5, pp. 951–957, 2014.

[19] D. R. Fintak, G. K. Shah, K. J. Blinder et al., “Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab,” Retina, vol. 28, no. 10, pp. 1395–1399, 2008.

[20] S. Pilli, A. Kotsolis, R. F. Spaide et al., “Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting,” American Journal of Ophthalmology, vol. 145, no. 5, pp. 879–882, 2008.

[21] P. D. Williams, D. Chong, T. Fuller, and D. Callanan, “Noninfectious vitritis after intravitreal injection of anti-VEGF agents,” Retina, vol. 36, no. 5, pp. 909–913, 2016.

[22] K. Yamashiro, A. Tsujikawa, K. Miyamoto et al., “Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch,” Retina, vol. 30, no. 3, pp. 485–490, 2010.

[23] M. Entezari, A. Ramezani, H. Ahmadieh, and H. Ghasemi, “Batch-related sterile endophthalmitis following intravitreal injection of bevacizumab,” Indian Journal of Ophthalmology, vol. 62, no. 4, pp. 468–471, 2014.

[24] V. Daen, V. Nguyen, R. W. Essex et al., “Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration,” Ophthalmology, vol. 125, no. 1, pp. 66–74, 2018.

[25] S. E. Geerlings and A. I. M. Hoepelman, “Immune dysfunction in patients with diabetes mellitus (DM),” FEMS Immunology & Medical Microbiology, vol. 26, no. 3-4, pp. 259–265, 1999.

[26] P. G. Montan, G. Koranyi, H. E. Setterqust, A. Stridh, B. T. Philipson, and K. Wiklund, “Endophthalmitis after cataract surgery: risk factors relating to technique and events of the operation and patient history,” Ophthalmology, vol. 105, no. 12, pp. 2171–2177, 1998.

[27] S. M. Cohen, H. W. Flynn Jr., T. G. Murray et al., “Endophthalmitis after pars plana vitrectomy,” Ophthalmology, vol. 102, no. 5, pp. 705–712, 1995.

[28] N. Rayess, E. Rahimy, C. P. Shah et al., “Incidence and clinical features of post-injection endophthalmitis according to diagnosis,” British Journal of Ophthalmology, vol. 100, no. 8, pp. 1058–1061, 2016.

[29] K. Mithal, A. Mathai, A. Pathengay et al., “Endophthalmitis following intravitreal anti-VEGF injections in ambulatory surgical centre facility: incidence, management and outcome,” British Journal of Ophthalmology, vol. 97, no. 12, pp. 1609–1612, 2013.

[30] N. Rayess, E. Rahimy, P. Storey et al., “Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept,” American Journal of Ophthalmology, vol. 165, pp. 88–93, 2016.

[31] D. A. Friedman, J. O. Mason, T. Emond, and G. Mcgwin, “Povidone-iodine contact time and lid speculum use during intravitreal injection,” Retina, vol. 33, no. 5, pp. 975–981, 2013.

[32] Y. Ahmed, I. U. Scott, A. Pathengay, A. Bawdekar, and H. W. Flynn, “Povidone-iodine for endophthalmitis prophylaxis,” American Journal of Ophthalmology, vol. 157, no. 3, pp. 503–504, 2014.

[33] P. Storey, M. Dollin, R. Nadeem et al., “The effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection,” Graefes Archive for Clinical and Experimental Ophthalmology, vol. 254, no. 2, pp. 235–242, 2016.

[34] P. Storey, M. Dollin, J. Pitcher et al., “The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection,” Ophthalmology, vol. 121, no. 1, pp. 283–289, 2014.

[35] M. Reibaldi, A. Pulvirenti, T. Avitabile et al., “Pooled estimates of incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents with
and without topical antibiotic prophylaxis," Retina, vol. 38, no. 1, pp. 1–11, 2018.

[36] A. P. Hunyor, R. Merani, A. Darbar, J.-F. Korobelnik, P. Lanzetta, and A. A. Okada, “Topical antibiotics and intravitreal injections,” Acta Ophthalmologica, vol. 96, no. 5, pp. 435–441, 2018.

[37] T. W Stone, “ASRS 2015 Preferences and trends membership survey,” 2015, http://www.asrs.org/content/documents/_2015-pat-survey-results.pdf.

[38] T. W. Stone, “ASRS 2016 Preferences and trends membership survey,” 2016, http://www.asrs.org/content/documents/_2016-pat-survey-results.pdf.

[39] P. P. Storey, Z. Tauqeer, Y. Yonekawa et al., “The impact of prefilled syringes on endophthalmitis following intravitreal injection of ranibizumab,” American Journal of Ophthalmology, vol. 199, pp. 200–208, 2019.

[40] P. Mahalingam, T. Topiwala, and G. Ganesan, “Drug-resistant coagulase-negative staphylococcal endophthalmitis following dexamethasone intravitreal implant,” Indian Journal of Ophthalmology, vol. 65, no. 7, pp. 634–636, 2017.

[41] Y. J. Cruz-Iñigo, K. Klein, and R. K. Reddy, “Case report of abiotrophia defectiva endophthalmitis after repeated injections of dexamethasone intravitreal implant (ozurdex),” Retinal Cases & Brief Reports, 2019.